FTH (Faeth Therapeutics) Book Value per Share: $-102.45 (As of Mar. 2026)


FTH Faeth Therapeutics Inc FTH
21 GF Score
Price $24.96
! 2 Warning Signs
View Full Analysis

What is Faeth Therapeutics Book Value per Share?

Faeth Therapeutics FTH +0.70% 21 Book Value per Share is $-102.45 as of Mar. 2026. GuruFocus rates FTH with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Faeth Therapeutics's book value per share for the quarter that ended in Mar. 2026 was $-102.45.

During the past 12 months, Faeth Therapeutics's average Book Value Per Share Growth Rate was -51.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -39.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Faeth Therapeutics was -31.70% per year. The lowest was -39.70% per year. And the median was -35.70% per year.

Faeth Therapeutics's current price is $24.96. Its book value per share for the quarter that ended in Mar. 2026 was $-102.45. Hence, today's PB Ratio of Faeth Therapeutics is .


Faeth Therapeutics  (NAS:FTH) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Faeth Therapeutics Book Value per Share Related Terms


Faeth Therapeutics Book Value per Share Historical Data

* Premium members only.

The historical data trend for Faeth Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faeth Therapeutics Book Value per Share Chart

Faeth Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
Get a 7-Day Free Trial 95.76 67.24 51.83 30.49 14.73

Faeth Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.39 21.66 18.25 14.73 -102.45

FTH vs NEUP, KYNB, CRVO: Book Value per Share Comparison

For the Biotechnology subindustry, Faeth Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faeth Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faeth Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Faeth Therapeutics's PB Ratio falls into.


FTH
21GF Score
Faeth Therapeutics Inc FTH
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faeth Therapeutics Book Value per Share Calculation

Faeth Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(18.59-0.00)/1.26
=14.73

Faeth Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2026 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-137.29-0.00)/1.34
=-102.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $-102.45 mean?
Faeth Therapeutics (FTH) has a Book Value per Share of $-102.45 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Faeth Therapeutics and its competitors.
Is Faeth Therapeutics' Book Value per Share too high?
Faeth Therapeutics' current Book Value per Share is $-102.45. Overall, Faeth Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Faeth Therapeutics' Book Value per Share compare to NEUP and KYNB?
Faeth Therapeutics' Book Value per Share of $-102.45 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Faeth Therapeutics and its competitors. Faeth Therapeutics's current Book Value per Share is $-102.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faeth Therapeutics stock overvalued right now?
Faeth Therapeutics (FTH) has a current Book Value per Share of $-102.45. The current Book Value per Share is $-102.45. Faeth Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Faeth Therapeutics (FTH), the current Book Value per Share is $-102.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faeth Therapeutics Business Description

Address 701 Tillery Street No. 12, No.1010, Austin, TX, USA, 78702
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
21GF Score

Get the complete analysis for FTH

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.96
Price